Bitcoin -26.98
$10,666.54 -0.25298%
Ethereum 2.95
$352.48 0.83638%
XRP 0.00
$0.24 -0.02493%
Zcash -0.16
$54.28 -0.28634%
Monero 1.58
$95.17 1.6647%
Tether 0.00
$1.00 0.04963%
Elite 0.00
$0.00 -3.85306%
Dendritic Cell-Targeting Therapeutic Vaccine
Token sale completed on 27 September
Goal: 10 000 000 DER
Website Whitepaper

We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases. Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile. The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.

Token Sale: 27 September — 27 September
Ticker
ICO Token Price
Whitelist
Min/Max Personal Cap
Accepts
Screenshots
Short review
Number of team Members

Add a comment

Member of The Internet Defense League